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Abstract
Immune checkpoint inhibitors (ICIs) have become pivotal in the treatment
of lung cancer. An increasing number of immune-related adverse events
(irAEs) have been recognized with their use. To our knowledge, this is the
first published case of sarcoid-like pulmonary lymphadenopathy associated
with durvalumab, a monoclonal antibody against programmed death
ligand-1 (PD-L1). A 76-year-old woman received adjuvant durvalumab for
Stage IIA pT2aN1M0 (American Joint Committee on Cancer, Seventh edi-
tion) poorly differentiated lung adenocarcinoma. After three cycles, a sarcoid-
like granulomatous reaction was identified in mediastinal and hilar lymph
nodes. Although the lymphadenopathy remained stable in size with the ongo-
ing treatment, progressive intracranial metastases were identified after a fur-
ther three cycles of durvalumab. Sarcoid-like inflammation with the
formation of non-caseating granulomas in the absence of systemic sarcoidosis
is an irAE which may mimic disease progression. Although a subset of
patients who experience this reaction may have a favourable response to
checkpoint inhibition, progression of disease may occur contemporaneously.
Introduction
Immune checkpoint inhibitors (ICIs) are monoclonal anti-
bodies that enhance anti-tumour immunity by targeting
molecules which downregulate T-cell responses [1].
Immune-related adverse events (irAE) are toxicities
unique to checkpoint blockade and may affect any organ
system with varying severity. With the widespread use of
ICIs, there has been increased appreciation of rheumato-
logical irAEs [1]. Many of these share a similar phenotype
to those documented in the general population such as
systemic lupus erythematous, polymyalgia rheumatica, and
sarcoidosis [1].
Sarcoidosis is a granulomatous disease characterized by
the formation of non-caseating granulomas in multiple organ
systems [2]. Sarcoid-like granulomatous inflammation is an
uncommon irAE that has been associated with inhibition
of cytotoxic T lymphocyte antigen-4 (CTLA-4) with
ipilimumab, programmed death-1 (PD-1) with nivolumab
and pembrolizumab, and PD-L1 with atezolizumab and
avelumab [2–4]. We report a case of sarcoid-like granuloma-
tous lymphadenopathy associated with durvalumab, an anti-
PD-L1 selective human immunoglobulin G1 (IgG1) mono-
clonal antibody in a woman with lung adenocarcinoma.
Case Report
A 76-year-old woman was diagnosed with a Stage IIA
(pT2aN1M0) poorly differentiated lung adenocarcinoma
after presenting with haemoptysis and shoulder pain.
Whole-body positron emission tomography-computed
tomography (PET-CT) identified a spiculated 4.5 cm
18F-fluorodeoxyglucose (FDG)-avid lung mass in the
apicoposterior segment of the left upper lobe without evi-
dence of nodal or distant metastases. The patient under-
went a left upper lobe lobectomy and completed four
cycles of adjuvant chemotherapy (cisplatin and vin-
orelbine) in January 2019. The specimen was KRAS
mutant, ALK negative and EGFR/BRAF wild type with
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clear margins. One hilar lymph node was affected with
metastatic disease. Prominent anthracosilicosis with non-
necrotizing granulomatous inflammation was noted in
most lymph nodes sampled (Fig. 1).
Past medical history included hypertension, depression,
thyrotoxicosis, and hysterectomy. The patient was an ex-
tobacco smoker with a 40 pack-year-history.
The patient commenced the first cycle of adjuvant
durvalumab (20 mg/kg every four weeks for 12 months)
on 25 February 2019.
Routine whole-body non-contrast CT three months
after the initiation of durvalumab was suspicious for nodal
recurrence with interval development of mediastinal
lymphadenopathy. PET confirmed highly metabolically
active bilateral mediastinal and hilar lymphadenopathy in
addition to areas of increased FDG-uptake in the right
scapula, left iliac crest, posterior ilium, and a 4-mm right
upper lobe lung nodule.
Fine needle aspirate (FNA) samples obtained via
endobronchial ultrasound (EBUS) bronchoscopy (station
Figure 1. (A, B) Non-contrast computed tomography (CT) of the chest with bilateral mediastinal lymphadenopathy involving the right pre-tracheal
nodal station, left pre-vascular space, and subcarina. (C, D) Positron emission tomography (PET)-CT demonstrating highly metabolic active lymphade-
nopathy. (E, F) PET-CT three months after the cessation of durvalumab demonstrating complete resolution of metabolically active bilateral hilar and
mediastinal lymphadenopathy.
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7, 4R, and 11R) demonstrated epithelioid histiocytes
arranged in non-caseating granulomas. Anthracotic pig-
ment and flecks of polarizable silicotic material were iden-
tified in most of the granulomas. No malignant cells or
fungi were identified and both smear and culture for acid-
fast bacilli were negative. A diagnosis of durvalumab-
associated sarcoid-like lymphadenopathy was made. The
patient was asymptomatic and durvalumab was continued
with no delay to the treatment schedule.
Repeat CT staging was completed after the sixth cycle of
durvalumab in August 2019. Although there was no signif-
icant change in size of the mediastinal and hilar lymphade-
nopathy, a ring-enhancing lesion suspicious for metastatic
disease was identified in the right cerebellum. Subsequent
magnetic resonance imaging (MRI) of the brain confirmed
numerous intra-axial ring-enhancing lesions (Fig. 2).
Although the neuroimaging findings were considered
most consistent with intracranial metastases rather than
neurosarcoidosis, a two-week trial of high-dose predniso-
lone was commenced. MRI of the brain repeated following
this trial did not show any significant changes to the intra-
cranial lesions, supporting a diagnosis of intracranial
metastases. Durvalumab was ceased and the patient was
referred for whole-brain radiotherapy. Oral prednisolone
was continued at a dose of 25 mg daily. The dosage was
weaned over the course of two months prior to cessation
in October 2019.
Repeat PET-CT in November, three months after the
cessation of durvalumab, demonstrated complete resolu-
tion of the metabolically active bilateral hilar and mediasti-
nal lymphadenopathy. In addition, there was resolution of
the previously identified areas of increased FDG-uptake in
the right upper lobe, right scapula, and left ilium.
Discussion
The development of sarcoid-like granulomas with check-
point inhibition may mimic disease progression and pose a
clinical conundrum which may impact treatment deci-
sions. The most common sites of involvement are the
mediastinal and hilar lymph nodes (71% of cases), lung
parenchyma (60% of cases), and skin (54.5% of cases) [2].
It is presumed that sarcoid-like granulomas with ICIs
occur via a similar mechanism to systemic sarcoidosis with
a predominant type 1 T helper cell (Th1) response [2].
The cell-mediated immune response evoked by ICIs and
subsequent destruction of immunogenic tumour cells may
expose neoantigens which promote granulomatous inflam-
mation [5].
Pulmonary involvement may manifest with a wide
range of radiographic findings including bilateral patchy
ground-glass opacities, multifocal nodular changes, or focal
consolidation with or without accompanying lymphade-
nopathy [2,4].
Given that non-necrotizing granulomatous inflamma-
tion was present in the lymph nodes sampled at the time
of initial surgery, it is likely that there was a subclinical
granulomatous process present prior to commencement
of durvalumab. As these lymph nodes were not appreci-
ated on initial PET-CT and there are no prior images or
histological specimens for review, we cannot comment
on whether this process is related to her underlying
malignancy or was long-standing. The patient did not
have features of systemic sarcoidosis at the time of
presentation.
Despite the presence of non-necrotizing granulomatous
inflammation on the initial histological specimen, the com-
mencement of durvalumab was temporally related with an
Figure 2. Axial T1-weighted turbo-spin echo (TSE) magnetic resonance imaging (MRI) demonstrating multifocal enhancing cerebellar (A, B) and
cerebral lesions (C) with adjacent vasogenic oedema and no leptomeningeal involvement.
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increase in the size and degree of metabolic activity of the
hilar and mediastinal lymphadenopathy on PET-CT. This
suggests that this process may have been accelerated by
checkpoint inhibition.
As the patient received oral prednisolone for two
months after durvalumab was ceased, it is unclear whether
the resolution of lymphadenopathy on repeat PET-CT was
directly related to the cessation of checkpoint inhibition.
In this case, the appearance of intracranial metastatic
disease occurred in the setting of stable mediastinal and
hilar lymphadenopathy with ongoing administration of
durvalumab. Although sarcoid-like granulomas with ICIs
have been associated with a favourable therapeutic
response in a number of patients, this case is an example
of disease recurrence occurring in close temporal proxim-
ity to biopsy-proven sarcoid-like granulomas, emphasizing
the importance of close surveillance [5].
The differential diagnosis of neurosarcoidosis related to
durvalumab was considered in this case. However, this rare
manifestation was considered unlikely, given the absence
of changes on MRI after the course of high-dose cortico-
steroids and lack of leptomeningeal involvement. Further
investigations such as lumbar puncture or meningeal
biopsy were not undertaken.
Neurological involvement in systemic sarcoidosis and
sarcoid-like granulomas associated with ICIs most com-
monly affects the leptomeninges with evidence of
leptomeningeal enhancement and thickening on MRI [6].
However, MRI is not specific for neurosarcoidosis as there
is a diverse range of radiographic appearances including
parenchymal lesions which may mimic metastatic disease.
These lesions are typically enhancing and closely associ-
ated with leptomeningeal involvement [7].
As with targeted therapies against CTLA-4, PD-1, and
PD-L1, our case has demonstrated an association between
the anti-PD-L1 durvalumab and sarcoid-like granuloma-
tous lymphadenopathy.
In conclusion, in patients receiving ICIs, the develop-
ment of sarcoid-like granulomas and disease progression
can occur contemporaneously. This case highlights the
importance of ongoing surveillance for progressive or
recurrent disease in this cohort. Further research is
required to establish the natural history of this phenome-
non and its relationship with tumour progression.
Disclosure Statement
Appropriate written informed consent was obtained for
publication of this case report and accompanying images.
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